Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Can you beat 50% per month? -- Ignore unavailable to you. Want to Upgrade?

To: Smiling Bob who wrote (9507)	4/6/2006 10:37:58 AM
From: Smiling Bob	Respond to of 19256

GTHA news found .18 x .185 PURIVAX (TM) Technology from GeneThera Can Facilitate Faster Development of Avian Flu Vaccine Thursday April 6, 10:00 am ET WHEAT RIDGE, Colo.--(BUSINESS WIRE)--April 6, 2006--GeneThera (OTCBB:GTHA - News) announces that its Purivax(TM) technology -- a large-scale process for highly purified and high viral titer Adenovirus and AAV recombinant vectors, would enable fast track development of Adenovirus and AAV-based recombinant DNA vaccines for diseases such as the Avian Flu (commonly called Bird Flu). GeneThera's PURIVAX(TM), is a multi-resin anion exchange chromatography system that dramatically improves biological purity and viral titer of recombinant Adenovirus and AAV vectors. PURIVAX(TM), completely eliminates toxic side effects associated with adenoviruses and AAV vectors thereby making it possible to quickly develop highly immunogenic and safe recombinant DNA vaccines, which are significantly more efficacious in fighting today's bacterial and viral diseases like Bird Flu, as well as food pathogen applications. Importantly, recombinant DNA (rDNA) vaccine technology represents a powerful tool for an innovative vaccine design process known as "genetic immunization." Dr. Tony Milici, CEO of GeneThera remarked, "GeneThera's PURIVAX(TM) is able to achieve both high purity and high viral titer (up to 10e16 viral particles/eulate) based on its proprietary multi-resin anion exchange chromatography system, unlike traditional technologies and first generation chromatography processes that are inadequate, both in terms of purity and yield. The important significance to mankind is that our PURIVAX(TM) technology can help achieve accelerated development of an rDNA vaccine for veterinary diseases, such as the Bird Flu." ABOUT GENETHERA, INC.: GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company's proprietary diagnostic solution is based on a genetic expression assay, GEA(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Mad Cow disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johne's Disease, diseases affecting cattle worldwide. ``Safe Harbor'' Statement: Certain statements in this release are ``forward-looking'' statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital. Contact: GeneThera, Inc. Dr. Tony Milici, 303-463-6371 genethera.net Source: GeneThera, Inc.